Drug intelligence / Profile preview

ID-LctPR-40

Development stage: Unknown
Lead developer: Lycotec

Overview

ID-LctPR-40 is an investigational Lycotec drug candidate in Phase 2 proof-of-concept development for prostate hyperplasia and prostate cancer. Publicly available pipeline information identifies it as a specific program from Lycotec, but does not disclose a validated molecular target, active ingredient, formulation details, route of administration, or mechanism of action. Based on the available source material, it is best described as an early clinical prostate disease asset with undisclosed pharmacology being evaluated across benign and malignant prostate indications.

Beyond the preview

Go deeper on ID-LctPR-40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ID-LctPR-40.

Explore the full profile